(19)
(11) EP 2 516 420 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.10.2018 Bulletin 2018/42

(45) Mention of the grant of the patent:
22.08.2018 Bulletin 2018/34

(21) Application number: 10799037.6

(22) Date of filing: 22.12.2010
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
C07D 403/14(2006.01)
A61K 31/506(2006.01)
A61P 37/08(2006.01)
 C07D 403/04(2006.01)
C07D 409/14(2006.01)
A61P 29/00(2006.01)
(86) International application number:
PCT/EP2010/070562
(87) International publication number:
WO 2011/076878 (30.06.2011 Gazette 2011/26)

(54)

AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS

AMINOALKYLPYRIMIDIN-DERIVATE ALS HISTAMIN-H4-REZEPTOR-ANTAGONISTEN

DÉRIVÉS D'AMINOALKYLPYRIMIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR H4 DE L'HISTAMINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 23.12.2009 EP 09382302
24.02.2010 US 307579 P

(43) Date of publication of application:
31.10.2012 Bulletin 2012/44

(73) Proprietor: Medicis Pharmaceutical Corporation
Bridgewater, NJ 08807 (US)

(72) Inventors:
  • CARCELLER GONZÁLEZ, Elena
    E-08190 Sant Cugat del Vallès (ES)
  • VIRGILI BERNADO, Marina
    E-08023 Barcelona (ES)
  • SOLIVA SOLIVA, Robert
    E-08980 Sant Feliu de Llobregat (ES)
  • FERRER COSTA, Carles
    E-08370 Calella (ES)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
EP-A- 1 505 064
WO-A-2009/068512
WO-A1-2006/110763
 WO-A-2004/039796
WO-A-2009/080721
   
  • COWART M D ET AL: "Rotationally Constrained 2,4-Diamino-5,6-disubstituted Pyrimidines: A New Class of Histamine H4 Receptor Antagonists with Improved Druglikeness and in Vivo Efficacy in Pain and Inflammation Models", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 51, 26 September 2008 (2008-09-26), pages 6547-6557, XP002543231, ISSN: 0022-2623 [retrieved on 2008-09-26]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).